# Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma

> **NCT01947062** · PHASE3 · UNKNOWN · sponsor: **Swami Rama Cancer Hospital and Research Institute** · enrollment: 60 (estimated)

## Conditions studied

- Lung Cancer
- Squamous Cell Carcinoma of the Lung
- Locally Advanced and Metastatic Squamous Cell Carcinoma of the Lung

## Interventions

- **DRUG:** Intravenous Cisplatin & etoposide
- **DRUG:** Intravenous Cisplatin & etoposide along with oral cyclophosphamide

## Key facts

- **NCT ID:** NCT01947062
- **Lead sponsor:** Swami Rama Cancer Hospital and Research Institute
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-10
- **Primary completion:** 2014-06
- **Final completion:** 2014-10
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2013-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01947062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01947062, "Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01947062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*